Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have received an average rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $6.40.
Several brokerages have commented on APTO. Zacks Investment Research cut shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. HC Wainwright set a $9.00 price target on shares of Aptose Biosciences and gave the stock a “buy” rating in a research note on Friday, March 22nd. Citigroup began coverage on shares of Aptose Biosciences in a research note on Friday, January 25th. They issued an “outperform” rating and a $6.00 price target on the stock. Oppenheimer began coverage on shares of Aptose Biosciences in a research note on Thursday, January 24th. They issued an “outperform” rating and a $6.00 price target on the stock. Finally, Royal Bank of Canada began coverage on shares of Aptose Biosciences in a research note on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target on the stock.
APTO opened at $2.28 on Friday. Aptose Biosciences has a fifty-two week low of $1.57 and a fifty-two week high of $4.55. The firm has a market cap of $94.62 million, a P/E ratio of -2.65 and a beta of 1.57.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). As a group, research analysts expect that Aptose Biosciences will post -0.72 earnings per share for the current year.
In other news, Director Erich Platzer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $2.19, for a total value of $43,800.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Gregory K. Chow bought 15,000 shares of Aptose Biosciences stock in a transaction dated Wednesday, March 13th. The stock was acquired at an average price of $1.75 per share, for a total transaction of $26,250.00. Following the completion of the acquisition, the chief financial officer now owns 122,014 shares in the company, valued at $213,524.50. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 35,000 shares of company stock worth $63,750.
Institutional investors have recently bought and sold shares of the company. Noven Financial Group Inc. bought a new stake in shares of Aptose Biosciences in the 4th quarter worth about $27,000. Geode Capital Management LLC bought a new position in Aptose Biosciences during the 4th quarter valued at about $33,000. Boston Advisors LLC bought a new position in Aptose Biosciences during the 1st quarter valued at about $36,000. Patriot Financial Group Insurance Agency LLC grew its holdings in Aptose Biosciences by 11.4% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 5,890 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Aptose Biosciences during the 1st quarter valued at about $198,000. Hedge funds and other institutional investors own 7.79% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also: The Structure of a Futures Contract
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.